• Visual analogue scale-Fatigue (VAS-F, total score ranged 0 [fatigued not at all] to 100 [extremely fatigued]) [ Time Frame: 12 weeks ]
  Improvement of FACIT-VAS after using KRG
• ESSDAI (The EULAR Sjögren's syndrome [SS] disease activity index, total score ranged 0 to 123, higher scroes indicate severe systemic disease activity) [ Time Frame: 12 weeks ]
  Improvement of ESSDAI after using KRG
• EuroQol 5 dimensions questionnaire (EQ-5D, a person's health status is defined by a 5-digit number, ranging from 11111 [having no problems in all dimensions] to 33333 [having extreme problems in all dimensions]) [ Time Frame: 12 weeks ]
  Improvement of EQ-5D after using KRG

• Fatigue visual analogue scale (VAS) [ Time Frame: 12 weeks ]
  Improvement of FACIT-VAS after using KRG
• ESSDAI [ Time Frame: 12 weeks ]
  Improvement of ESSDAI after using KRG
• EuroQol 5 dimensions questionnaire (EQ-5D) [ Time Frame: 12 weeks ]
  Improvement of EQ-5D after using KRG

Primary objective

: Improvement of fatigue after using KRG in patients with rheumatic diseases according to

Secondary objectives

1. Improvement of dryness after using KRG in patients with rheumatic diseases according to EULAR Sjögren's syndrome disease activity index (ESSDAI)
2. Improvement of quality of life after using KRG in patients with rheumatic diseases according to EuroQol 5 dimensions questionnaire (EQ-5D)

The study population will be adult patients with rheumatic diseases, especially primary or secondary Sjögren's syndrome who have experienced dryness for more than 3 months. Participants are ramdomly assigned to KRG and placebo group and they are using KRG or placebo for the first 12 weeks. After 12 weeks, the concealment of allocation is lifted and all patients are provided with KRG for next 12 weeks with open-label extension study

• Sjögren's Syndrome
• Rheumatic Diseases
• Korean Red Ginseng

• Dietary Supplement: Korean Red Ginseng
  Participants are provided with 2 Korean Red Ginseng extract tablets twice a day for total 24 weeks.
  Other Name: KRG
• Dietary Supplement: Placebo
  Placebo tablets, made of corn starch and cellulose, are manufactured to mimic KRG tablets. Participants are parovided with 2 placebo tablets twice a day for first 12 weeks, following Korean Red Ginseng extract tablets twice a day for another 12 weeks.

• Active Comparator: KRG group
  • Enrollment: 60 patients
  • Drug: Korean Red Ginseng (KRG) 2,000 mg/day for total 24 weeks (2 Korean Red Ginseng extract tablet twice a day, ginsenoside Rg1+Rb1+Rg3 7.0 mg/g per each tablet)
  Intervention: Dietary Supplement: Korean Red Ginseng
• Placebo Comparator: Placebo group
  • Enrollment: 60 patients
  • Drug: Placebo for 12 weeks, following Korean Red Ginseng 2,000mg/day for another 12 weeks
  Intervention: Dietary Supplement: Placebo

Inclusion Criteria:

• Patients who meet for Classification Criteria for Sjögren's syndrome
• Patients who have experienced fatigue for over 3 months
• Patients aged ≥ 19 and <75
• Patients who provide a written consent of participating in this study.

Exclusion Criteria:

• Patients who have experienced hypersensitivity or adverse events to Korean Red ginseng
• Patients who used dietary supplements containing KRG during recent 2 months
• Patients who are pregnant or breast-feeding
• Patients who use oral glucocorticoids or opioids continuously
• Patients who had other comorbidities which could lead to fatigue as symptoms including chronic kidney disease, chronic liver disease, endocrine disoders, malignancy, or depression.
• Patients having fibromyalgia or chronic fatigue syndrome
• Patients who presented abnormal laboratory findings at the time of enrollment White blood cell (WBC) ≤ 3.5 x 10^9/L or, Hemoglobin (Hb) ≤ 8.5 g/dL or, Platelet (PLT) ≤ 100 x 10^9/L or, Serum creatinine (Cr) ≥ 2.0 mg/dL or, Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥ 2.5 times of upper limits of normal